Limited efficacy of lamivudine against hepatitis B virus infection in allogeneic hematopoietic stem cell transplant recipients

Transplantation

Volumn 73, Issue 5, 2002, Pages 812-815

  Ohnishi, Mutsuko ^a   Kanda, Yoshinobu ^a   Takeuchi, Toshio ^a   Won Kim, Sung ^a   Hori, Akiko ^a   Niiya, Hironari ^a   Chizuka, Aki ^a   Nakai, Kunihisa ^a   Saito, Takeshi ^a   Makimoto, Atsushi ^a   Tanosaki, Ryuji ^a   Watanabe, Takashi ^a   Kobayashi, Yukio ^a   Tobinai, Kensei ^a   Takaue, Yoichi ^a   Mineishi, Shin ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; LAMIVUDINE; STEROID;

ADULT; ALLOGENEIC RESTRICTION; ARTICLE; CASE REPORT; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL; STEROID THERAPY; VIRUS LOAD; VIRUS REACTIVATION;

EID: 0037087581     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200203150-00027     Document Type: Article

References (12)

1. Hepatitis viruses and hematopoietic cell transplantation: A guide to patient and donor management
2. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem
3. Lamivudine as initial treatment for chronic hepatitis B in the United States
4. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis
5. Efficacy and safety of lamivudine on replication of recurrent hepatitis B after cadaveric renal transplantation
6. Lamivudine for the prevention of hepatitis B virus reactivation during autologous stem cell transplantation: A case report
7. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation
8. A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
9. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
10. Allogeneic bone marrow transplantation from HBsAg+ donors: A multicenter study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
11. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation
12. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy